Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author García-Sanz, Ramónca
• dc.contributor.author Albert, Oriolca
• dc.contributor.author Moreno, María J.ca
• dc.contributor.author Rubia, Javier de laca
• dc.contributor.author Payer, Angel R.ca
• dc.contributor.author Hernández, Miguel T.ca
• dc.contributor.author Palomera, Luisca
• dc.contributor.author Teruel, Ana I.ca
• dc.contributor.author Blanchard, María J.ca
• dc.contributor.author Gironella, Mercedesca
• dc.contributor.author Ribas, Pazca
• dc.contributor.author Bargay, Joanca
• dc.contributor.author Abella Monreal, Eugeniaca
• dc.contributor.author Granell, Miquelca
• dc.contributor.author Ocio, Enrique M.ca
• dc.contributor.author Ribera, Josep Mariaca
• dc.contributor.author San Miguel, Jesús F.ca
• dc.contributor.author Mateos, María V.ca
• dc.contributor.author Spanish Myeloma Group (GEM/PETHEMA).ca
• dc.date.accessioned 2015-11-24T12:40:09Z
• dc.date.available 2015-11-24T12:40:09Z
• dc.date.issued 2015
• dc.description.abstract This study analyzed the anti-myeloma effect of zoledronic acid monotherapy by investigating patients at the time of asymptomatic biochemical relapse. One hundred patients were randomized to receive either zoledronic acid (4 mg iv/4 weeks, 12 doses) (n=51) or not (n=49). Experimental and control groups were well balanced for disease and prognostic features. Zoledronic acid did not show an antitumor effect according to changes in M-component. However, there were fewer symptomatic progressions in the experimental group than in the control group (34 versus 41, respectively; P=0.05) resulting in a median time to symptoms of 16 versus 10 months (P=0.161). The median time to next therapy was also slightly longer for the treated group than the untreated, control group (13.4 versus 10.1 months), although the difference was not statistically significant (P=0.360). The pattern of relapses was different for treated versus control patients: progressive bone disease (8 versus 20), anemia (24 versus 18), renal dysfunction (1 versus 2), and plasmacytomas (1 versus 1, respectively). This concurred with fewer skeletal-related events in the treated group than in the control group (2 versus 14), with a projected 4-year event proportion of 6% versus 40% (P<0.001). In summary, zoledronic acid monotherapy does not show an antitumor effect on biochemical relapses in multiple myeloma, but does reduce the risk of progression with symptomatic bone disease and skeletal complications. This trial was registered in the ClinicalTrials.gov database with code NCT01087008.ca
• dc.description.sponsorship This work was supported by an unrestricted grant from Novartis Farmaceutica S.A., Barcelona, Spain and sponsored by GEM/PETHEMA. Part of the work was also done thanks to grants PS09/01450 and PI12/02311 from the Spanish “Instituto de Salud Carlos III (ISCIII)” and Fondo Europeo de Desarrollo Regional (FEDER), the Spanish Ministry of Economy and Competitiveness and the European Regional Development Fund (ERDF) “Una manera de hacer Europa” (Innocampus; CEI-2010-1-0010), the grant RD12/0036/0069 from “Red Temática de Investigación Cooperativa en Cáncer (RTICC), and grant GCB-120981SAN from the “Asociación Española Contra el Cáncer (AECC)”.
• dc.format.mimetype application/pdfca
• dc.identifier.citation García-Sanz R, Oriol A, Moreno MJ, de la Rubia J, Payer AR, Hernández MT, Palomera L, Teruel AI, Blanchard MJ, Gironella M, Ribas P, Bargay J, Abellá E, Granell M, Ocio EM, Ribera JM, San Miguel JF, Mateos MV. Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial. Haematologica. 2015;100(9)
• dc.identifier.doi http://dx.doi.org/10.3324/haematol.2015.128439
• dc.identifier.issn 0390-6078
• dc.identifier.uri http://hdl.handle.net/10230/25195
• dc.language.iso engca
• dc.publisher Ferrata Storti Foundationca
• dc.relation.ispartof Haematologica. 2015;100(9)
• dc.rights ©2015 Ferrata Storti Foundation. This is an open-access paper. http://dx.doi.org/10.3324/haematol.2015.128439ca
• dc.rights.accessRights info:eu-repo/semantics/openAccessca
• dc.subject.other Mieloma múltipleca
• dc.title Zoledronic acid as compared with observation in multiple myeloma patients at biochemical relapse: results of the randomized AZABACHE Spanish trial.ca
• dc.type info:eu-repo/semantics/articleca
• dc.type.version info:eu-repo/semantics/publishedVersionca